meglumine antimoniate

Known as: 1-deoxy-1- (methylamino)glucitol antimonate(V), N-methylglucamine antimonate, meglumine antimonate 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1964-2018
0102019642018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Resistance of Leishmania parasites to specific chemotherapy has become a well-documented problem in the Indian subcontinent in… (More)
Is this relevant?
2009
2009
We report a case of drug hypersensitivity syndrome (drug reaction with eosinophilia and systemic symptoms [DRESS]) induced by… (More)
Is this relevant?
2008
2008
A real-time PCR assay was exploited for monitoring the Leishmania DNA load in different tissues from 18 naturally-infected dogs… (More)
Is this relevant?
2007
2007
BACKGROUND Cutaneous leishmaniasis is a serious public health problem in the developing world. The main therapeutic agent… (More)
Is this relevant?
2004
2004
BACKGROUND Cutaneous leishmaniasis (CL) is a parasitic disease caused by Leishmania species. There is a need for more effective… (More)
Is this relevant?
2004
2004
The randomized, controlled study compared the therapeutic efficacy and safety of two paromomycin-containing topical preparations… (More)
Is this relevant?
2001
2001
The standard treatment of human leishmaniases involves the use of pentavalent antimony [Sb(V)] compounds, including meglumine… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2001
2001
Meglumine antimoniate (MA) is a pentavalent antimonial (Sb(V)) drug used to treat leishmaniasis. Despite the fact that Sb(V… (More)
Is this relevant?
1999
1999
The leishmanicidal drug, meglumine antimoniate (MA), has been synthesized by the reaction of antimony oxyhydrated and N-methyl… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
1999
1999
BACKGROUND Pentavalent antimonials have became of basic importance for the treatment of leishmaniasis. Their most severe side… (More)
Is this relevant?